(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 September 2025 (25.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/199170 A9

(51) International Patent Classification:
C07D 471/04 (2006.01) *A61K 31/519* (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:
PCT/US2025/020472

(22) International Filing Date:
18 March 2025 (18.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/CN2024/082455
19 March 2024 (19.03.2024) CN

(71) Applicant: **FRONTIER MEDICINES CORPORATION** [US/US]; 151 Oyster Point Blvd., 2nd Floor, South San Francisco, California 94080 (US).

(72) Inventors: **PATEL, Snahel**; c/o Frontier Medicines Corporation, 151 Oyster Point Blvd., 2nd Floor, South San Francisco, California 94080 (US). **XU, Jun**; c/o Crystal Pharmatech Co., Ltd, B4-101, Biobay, 218 Xinghu Street, Suzhou Industrial Park, Suzhou, Jiangsu 215123 (CN). **JI, Lingtao**; c/o Crystal Pharmatech Co., Ltd, B4-101, Biobay, 218 Xinghu Street, Suzhou Industrial Park, Suzhou, Jiangsu 215123 (CN). **WANG, Ruonan**; c/o Crystal Pharmatech Co., Ltd, B4-101, Biobay, 218 Xinghu Street, Suzhou Industrial Park, Suzhou, Jiangsu 215123 (CN). **ZHAO, Xin**; c/o Crystal Pharmatech Co., Ltd, B4-101, Biobay, 218 Xinghu Street, Suzhou Industrial Park, Suzhou, Jiangsu 215123 (CN).

(74) Agent: **DO, Keunbong** et al.; Morrison & Foerster LLP, 425 Market Street, San Francisco, California 94105 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

(48) Date of publication of this corrected version:
20 November 2025 (20.11.2025)

(15) Information about Correction:
see Notice of 20 November 2025 (20.11.2025)

WO 2025/199170 A9

(54) Title: POLYMORPHIC FORMS OF KRAS INHIBITORS AND USES THEREOF

(57) Abstract: The present disclosure relates generally to polymorphic forms of a KRAS inhibitor, and more specifically to polymorphic forms of a pyridopyrimidine derivative, and uses thereof.